Where the category stands in May 2026 — what's available, who to trust, what costs what. 22-min read, medically reviewed.
Read the guideAn independent overview of the compounded-GLP-1 telehealth market and the providers we cover — market size, what the FDA changed, and an honest read on each.
View the provider overviewOverview & reviewsPrimers for newcomers and deep dives for the curious. The foundation articles are published; more are in the pipeline.
View all Learn articlesWhat compounded and branded semaglutide and tirzepatide actually cost, from each provider's own published pricing.
Prescriber-facing summaries — dosing as reported in the literature, titration context, and the evidence behind it. Source-cited, independent, and never a substitute for clinical judgment.
These are editorial summaries of published dosing and evidence, for reference only. They don't constitute medical advice or a treatment protocol; prescribing decisions rest with the licensed clinician and the individual patient.
Standardized, downloadable protocol packs are in preparation. In the meantime, the dosing references, titration context, and safety notes prescribers ask about already live on each peptide's reference page — source-cited and dated. Start from the library, or the category landings below.
Semaglutide, tirzepatide, retatrutide, liraglutide — dosing & titration references.
Open category →CategoryBPC-157, TB-500 and the recovery set — what the evidence supports.
Open category →CategoryEpitalon, thymalin, NAD+, MOTS-c — references and caveats.
Open category →Standardized, prescriber-facing PDFs by category.
Coming soon